drugset / Trial / NCT02037165

Effectiveness of Two Different Doses of BI 1026706 on the Overall Peak-to-Peak (PtP) N2/P2-component Amplitude of Laser (Somatosensory, Radiant-heat) Evoked Potentials (LEP) in UVB(Ultraviolet)-Irradiated Skin in Healthy Male Volunteers

NCT02037165

Phase 1 Completed 25 enrolled Boehringer Ingelheim
RandomizedCrossoverSingle-blindTreatment

Summary

* To investigate the influence of different doses of BI 1026706 on the primary endpoint (PtP-amplitude LEP in UV skin) compared to placebo. * The comparison of both doses of BI 1026706 to celecoxib in the UVB treatment. * Comparison of both doses of BI 1026706 to placebo and pregabalin in the capsaicin treatment * Exploration of the pharmacokinetics of BI 1026706 * Exploration of safety and tolerability of BI 1026706

Timeline

Start
2014-01-21
Primary completion
2014-04-09
Completion
2014-04-15

Drugs

EvaluationDrugModalityDoseRoute
Subject BI 1026706 Unknown Oral
Subject Celecoxib Other / unclassified
Subject Pregabalin Small molecule

Indications

No indication recorded.